Holen Sie sich die Stockscreener-App
2.44
6.09%
0.14
Context Therapeutics Inc Aktie (CNTX) Neueste Nachrichten
Context Therapeutics settles governance lawsuit with mootness fee - TipRanks
Context Therapeutics (NASDAQ: CNTX) ends charter suit with $850K mootness fee - Stock Titan
H.C. Wainwright Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Context Therapeutics (CNTX) to Release Quarterly Earnings on Wednesday - MarketBeat
[ARS] Context Therapeutics Inc. SEC Filing - Stock Titan
Context Therapeutics (NASDAQ: CNTX) plans vote on board slate and 300M-share authorization - Stock Titan
Positive Signs As Multiple Insiders Buy Context Therapeutics Stock - Yahoo Finance
Context Therapeutics (CNTX) price target increased by 13.33% to 5.78 - MSN
Is Context Therapeutics (CNTX) stock a good candidate for diversification | Q4 2025: EPS Misses EstimatesMarket Risk - Xã Thanh Hà
CNTX (Context Therapeutics Inc.) shares rise 6.11 percent even as Q4 2025 EPS lands below consensus analyst estimates.Trending Volume Leaders - Cổng thông tin điện tử tỉnh Tây Ninh
Is Context Therapeutics (CNTX) stock forming lower lows | Q4 2025: EPS Misses EstimatesPayout Ratio - Xã Vĩnh Công
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Piper Sandler Reaffirms Their Buy Rating on Context Therapeutics (CNTX) - The Globe and Mail
Piper Sandler Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Context Therapeutics (CNTX) seeks 100M-share charter increase ahead of June meeting - Stock Titan
Targets Report: Can Context Therapeutics Inc maintain sales growth2026 PreEarnings & Entry and Exit Point Strategies - baoquankhu1.vn
Rally Mode: What makes Context Therapeutics Inc stock attractive todayWeekly Trend Recap & Stock Market Timing Techniques - baoquankhu1.vn
Is Context Therapeutics Inc likely to announce a buybackMarket Activity Report & Safe Entry Zone Identification - baoquankhu1.vn
History Review: What is Context Therapeutics Incs 5 year growth outlookTrade Analysis Report & Low Risk Profit Maximizing Plans - baoquankhu1.vn
CNTX Earnings History & Surprises | EPS & Revenue Results | CONTEXT THERAPEUTICS INC (NASDAQ:CNTX) - ChartMill
Investment Report: Will Context Therapeutics Inc stock go up in YEAR2026 Opening Moves & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Neogen names Jennifer Evans Stacey as chief legal officer - Investing.com
Food safety company Neogen taps biotech lawyer for legal, compliance post - Stock Titan
William Blair Initiates Coverage of Context Therapeutics (CNTX) with Outperform Recommendation - MSN
Breakouts Watch: How does Context Therapeutics Inc compare to its peers2026 Earnings Surprises & Growth Focused Entry Point Reports - baoquankhu1.vn
JonesTrading Remains a Buy on Context Therapeutics (CNTX) - The Globe and Mail
Buyout Rumor: Is Context Therapeutics Inc stock risky to hold now2026 Gainers & Long-Term Capital Growth Strategies - baoquankhu1.vn
JonesTrading Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Context Therapeutics Gains FDA Fast Track for CTIM-76 - The Globe and Mail
Published on: 2026-04-03 00:59:30 - baoquankhu1.vn
Context Therapeutics Shares Gain on FDA Fast Track Designation for Ovarian Cancer Drug - marketscreener.com
Context Therapeutics wins FDA fast-track status (CNTX:NASDAQ) - Seeking Alpha
Context Therapeutics' CTIM-76 Wins FDA Fast Track; Phase 1a Interim Data Due June 2026 - TradingView
FDA grants Fast Track to Context Therapeutics (CNTX) CTIM-76 in platinum-resistant ovarian cancer - Stock Titan
Context Therapeutics Receives FDA Fast Track Designation for CTIM-76 in Platinum-Resistant Ovarian Cancer - Quiver Quantitative
MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy - The Manila Times
Context Therapeutics Announces CTIM-76 Receives FDA Fast - GlobeNewswire
S P Trends: Can Context Therapeutics Inc maintain sales growth2026 Sector Moves & AI Based Trade Execution Alerts - baoquankhu1.vn
Support Test: Will Context Therapeutics Inc stock go up in YEARLayoff News & Fast Entry Momentum Alerts - baoquankhu1.vn
Context Therapeutics (NASDAQ:CNTX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - marketbeat.com
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Q1 EPS Forecast for Context Therapeutics Lowered by Analyst - MarketBeat
Gains Recap: What makes Context Therapeutics Inc stock attractive todayPortfolio Value Report & Technical Buy Zone Confirmations - baoquankhu1.vn
Insider Sell: Is Context Therapeutics Inc stock risky to hold now2026 Historical Comparison & Real-Time Volume Trigger Notifications - baoquankhu1.vn
HC Wainwright Brokers Reduce Earnings Estimates for CNTX - MarketBeat
Context Therapeutics (NASDAQ:CNTX) and Clearmind Medicine (NASDAQ:CMND) Head-To-Head Contrast - Defense World
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Context Therapeutics (NASDAQ:CNTX) Given Buy Rating at D. Boral Capital - Defense World
Context Therapeutics' (CNTX) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Context Therapeutics (NASDAQ:CNTX) Receives Buy Rating from Guggenheim - MarketBeat
Context Therapeutics (NASDAQ:CNTX) Price Target Raised to $7.00 - MarketBeat
Context Therapeutics 2025 Annual Report: Business Strategy, Risk Factors, Clinical Pipeline, and Regulatory Insights - Minichart
Context Therapeutics Reports Full Year 2025 Operating and Financial Results - National Today
According to the latest financial data, biopharmaceutical company Context Therapeutics Inc. (Context Therapeutics) held total cash and cash equivalents of $66 million as of December 31, 2025. - Bitget
Context Therapeutics Highlights Evolving T Cell Engager Pipeline - TipRanks
Context Therapeutics (NASDAQ:CNTX) Issues Quarterly Earnings Results - MarketBeat
Context Therapeutics Reports Full Year 2025 Operating And Financial Results - TradingView
Context Therapeutics Inc. Reports Financial Results and Upcoming Milestones for CTIM-76 and CT-95 Trials - Quiver Quantitative
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):